Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Neuromuscular Focused-Avidity Biosciences Has 'Complete Package' - Analyst Predicts Stellar 142% Stock Surge
Cantor Fitzgerald has initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA), noting the company has the complete package, including a strong management team, a proven platform, a robust pipeline, and a blockbuster product in deldesiran (formerly AOC 1001) for Myotonic dystrophy type 1 (DM1).
坎託·菲茨傑拉德已開始對Avidity Biosciences Inc（納斯達克股票代碼：RNA）進行報道，並指出該公司擁有完整的一攬子計劃，包括強大的管理團隊、久經考驗的平台、強大的產品線，以及一款針對1型肌強直性營養不良症（DM1）的deldesiran（前身爲AOC 1001）的重磅產品。
The analyst reports that Avidity has accumulated extensive biomarker and clinical data, significantly reducing the risks associated with their upcoming Phase 3 study.
該分析師報告說，Avidity已經積累了大量的生物標誌物和臨床數據，顯著降低了與即將進行的3期研究相關的風險。
Additionally, Dyne Therapeutics Inc (NASDAQ:DYN), a competitor trailing by approximately 12 months, is also generating similar data using a comparable approach, thereby offering further validation.
此外，落後約12個月的競爭對手達因療法公司（納斯達克股票代碼：DYN）也在使用類似的方法生成類似的數據，從而提供進一步的驗證。
Also Read: Avidity Biosciences Says Lead Program Shows Reversal Of Disease Progression In Neuromuscular Disease.
另請閱讀： Avidity Biosciences表示，主要項目顯示神經肌肉疾病的疾病進展出現逆轉。
Despite the potential variability in biomarker data obtained from muscle biopsies, Avidity's findings offer mechanistic support by demonstrating that del-desiran reduces DMPK RNA levels by 40-50% across various tested doses and has a dose-dependent effect on splicing mRNA.
儘管從肌肉活檢中獲得的生物標誌物數據可能存在差異，但Avidity的發現提供了機制支持，它證明del-desiran在各種測試劑量下將DMPK RNA水平降低了40-50％，並且對剪接mRNA具有劑量依賴性作用。
Cantor analyst notes that Del-desiran focuses on addressing the core issue of disease progression, specifically targeting the toxic accumulation of the DMPK transcript.
坎託分析師指出，Del-Desiran專注於解決疾病進展的核心問題，特別是針對DMPK轉錄本的毒性積累。
Phase 2 trials have demonstrated promising results, paving the way for a Phase 3 trial to commence in the second quarter of 2024.
2期試驗顯示出令人鼓舞的結果，爲2024年第二季度開始的3期試驗鋪平了道路。
Based on these advancements, projections anticipate U.S. sales reaching $1.3 billion by 2031.
基於這些進步，預計到2031年美國的銷售額將達到13億美元。
Cantor initiates with an Overweight rating and a price target of $60.
Cantor最初的增持評級和60美元的目標股價。
Avidity has two new clinical programs in Phase 1 development. One, AOC 1044, focuses on Duchenne Muscular Dystrophy that can be treated by skipping Exon 44, while the other, AOC 1020, targets facioscapulohumeral muscular dystrophy (FSHD).
Avidity 有兩個新的臨床項目處於第一階段開發階段。一種是AOC 1044，側重於杜興氏肌肉萎縮症，可通過跳過外顯子44進行治療，而另一個是AOC 1020，則針對面肩肱肌營養不良症（FSHD）。
Cantor notes that both programs utilize the same delivery mechanism as del-desiran, aim to tackle well-understood biological pathways, and hold the promise of becoming the first approved therapies for currently underserved patient groups.
坎託指出，這兩個項目都使用與del-desiran相同的給藥機制，旨在解決衆所周知的生物學途徑，並有望成爲目前服務不足的患者群體的首批獲批准的療法。
Price Action: RNA shares are down 3.54% at $23.95 on the last check Thursday.
價格走勢：在週四的最後一次支票中，RNA股價下跌3.54％，至23.95美元。
Illustration of Phrama lab worker created with MidJourney.
使用 MidJourney 創作的 Phrama 實驗室工作人員的插圖。